아이오 바이오텍(IOBT)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.00 (+100.00%), 시가총액 $0.00B, 52주 최저~최고 $0.00 ~ $2.40.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide to target T cells that recognize epitopes derived from Arg
아이오 바이오텍의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
아이오 바이오텍의 현재 주가는 $0.00 (+100.00%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
아이오 바이오텍의 시가총액은 약 $0.00B입니다.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vacci